Oncology Journals
Oncology journals cover clinical cancer care, translational oncology, tumour biology, prevention, diagnostics and treatment research. Citation patterns can vary between highly clinical and laboratory-focused titles.
257
Approved journals
Approved journals
257
With JIF
With JIF
97
Q1 journals
Q1 journals
232.400
Highest available JIF
Highest available JIF
Filter Oncology Journals
Oncology Journal List
257 results| Journal | JIF | 5-Year JIF | JCI | Quartile | Publisher |
|---|---|---|---|---|---|
| CA-A CANCER JOURNAL FOR CLINICIANS 0007-9235 |
232.400 | 353.000 | 112.160 | Q1 | WILEY |
| Nature Reviews Clinical Oncology 1759-4774 |
82.200 | 89.900 | 11.950 | Q1 | NATURE PORTFOLIO |
| NATURE REVIEWS CANCER 1474-175X |
66.800 | 81.000 | 9.040 | Q1 | NATURE PORTFOLIO |
| ANNALS OF ONCOLOGY 0923-7534 |
65.400 | 46.800 | 8.380 | Q1 | ELSEVIER |
| CANCER CELL 1535-6108 |
44.500 | 47.200 | 8.110 | Q1 | CELL PRESS |
| JOURNAL OF CLINICAL ONCOLOGY 0732-183X |
41.900 | 37.700 | 6.680 | Q1 | LIPPINCOTT WILLIAMS & WILKINS |
| Journal of Hematology & Oncology N/A |
40.400 | 34.400 | 5.040 | Q1 | BMC |
| LANCET ONCOLOGY 1470-2045 |
35.900 | 42.000 | 8.680 | Q1 | ELSEVIER SCIENCE INC |
| Molecular Cancer N/A |
33.900 | 35.900 | 5.040 | Q1 | BMC |
| Cancer Discovery 2159-8274 |
33.300 | 33.000 | 6.220 | Q1 | AMER ASSOC CANCER RESEARCH |
| Nature Cancer N/A |
28.500 | 28.600 | 5.360 | Q1 | NATURE PORTFOLIO |
| Cancer Communications N/A |
24.900 | 22.200 | 3.670 | Q1 | WILEY |
| Journal of Thoracic Oncology 1556-0864 |
20.800 | 18.400 | 4.240 | Q1 | ELSEVIER SCIENCE INC |
| JAMA Oncology 2374-2437 |
20.100 | 24.700 | 4.530 | Q1 | AMER MEDICAL ASSOC |
| Trends in Cancer 2405-8033 |
17.500 | 18.700 | 2.150 | Q1 | CELL PRESS |
| CANCER RESEARCH 0008-5472 |
16.600 | 13.400 | 2.340 | Q1 | AMER ASSOC CANCER RESEARCH |
| Journal of the National Comprehensive Cancer Network 1540-1405 |
16.400 | 13.200 | 2.910 | Q1 | HARBORSIDE PRESS |
| SEMINARS IN CANCER BIOLOGY 1044-579X |
15.700 | 15.500 | 3.460 | Q1 | ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD |
| Experimental Hematology & Oncology N/A |
13.500 | 11.300 | 1.950 | Q1 | BMC |
| NEURO-ONCOLOGY 1522-8517 |
13.400 | 16.000 | 3.440 | Q1 | OXFORD UNIV PRESS INC |
| JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH N/A |
12.800 | 12.200 | 2.450 | Q1 | BMC |
| Blood Cancer Journal 2044-5385 |
11.600 | 12.100 | 2.360 | Q1 | SPRINGERNATURE |
| Blood Cancer Discovery 2643-3230 |
11.500 | 11.500 | 2.830 | Q1 | AMER ASSOC CANCER RESEARCH |
| Journal for ImmunoTherapy of Cancer N/A |
10.600 | 11.500 | 2.160 | Q1 | BMJ PUBLISHING GROUP |
| CANCER TREATMENT REVIEWS 0305-7372 |
10.500 | 11.300 | 1.370 | Q1 | ELSEVIER SCI LTD |
| CLINICAL CANCER RESEARCH 1078-0432 |
10.200 | 11.200 | 2.360 | Q1 | AMER ASSOC CANCER RESEARCH |
| CANCER LETTERS 0304-3835 |
10.100 | 9.500 | 2.260 | Q1 | ELSEVIER IRELAND LTD |
| Journal of the National Cancer Center 2667-0054 |
9.400 | 8.000 | 1.750 | Q1 | ELSEVIER |
| European Urology Oncology N/A |
9.300 | 7.900 | 2.440 | Q1 | ELSEVIER |
| Liver Cancer 2235-1795 |
9.100 | 10.900 | 2.070 | Q1 | KARGER |
| CANCER AND METASTASIS REVIEWS 0167-7659 |
8.700 | 10.100 | 1.180 | Q1 | SPRINGER |
| Cancer Biology & Medicine 2095-3941 |
8.400 | 6.700 | 0.980 | Q1 | CHINA ANTI-CANCER ASSOC |
| BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER 0304-419X |
8.300 | 11.600 | 1.290 | Q1 | ELSEVIER |
| Cancer Immunology Research 2326-6066 |
8.200 | 10.200 | 1.830 | Q1 | AMER ASSOC CANCER RESEARCH |
| Tumour Virus Research 2666-6790 |
8.100 | 7.400 | 1.630 | Q1 | ELSEVIER |
| npj Precision Oncology N/A |
8.000 | 8.000 | 1.690 | Q1 | NATURE PORTFOLIO |
| npj Breast Cancer N/A |
7.600 | 7.300 | 1.500 | Q1 | NATURE PORTFOLIO |
| JNCI-Journal of the National Cancer Institute 0027-8874 |
7.200 | 9.300 | 1.930 | Q1 | OXFORD UNIV PRESS INC |
| EUROPEAN JOURNAL OF CANCER 0959-8049 |
7.100 | 7.500 | 1.600 | Q1 | ELSEVIER SCI LTD |
| BRITISH JOURNAL OF CANCER 0007-0920 |
6.800 | 8.600 | 1.400 | Q1 | SPRINGERNATURE |
| INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 0360-3016 |
6.500 | 6.500 | 1.590 | Q1 | ELSEVIER SCIENCE INC |
| Chinese Journal of Cancer Research 1000-9604 |
6.300 | 5.200 | 0.970 | Q1 | CHINESE JOURNAL CANCER RESEARCH CO |
| Radiology-Imaging Cancer 2638-616X |
6.300 | 5.600 | 1.170 | Q1 | RADIOLOGICAL SOC NORTH AMERICA (RSNA) |
| Annual Review of Cancer Biology 2472-3428 |
6.100 | 7.400 | 1.260 | Q1 | ANNUAL REVIEWS |
| Cancer Cell International N/A |
6.000 | 5.300 | 1.080 | Q1 | BMC |
| PROSTATE CANCER AND PROSTATIC DISEASES 1365-7852 |
5.800 | 5.300 | 1.370 | Q1 | SPRINGERNATURE |
| BREAST CANCER RESEARCH 1465-5411 |
5.600 | 7.000 | 1.300 | Q1 | BMC |
| CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 1040-8428 |
5.600 | 5.400 | 0.820 | Q1 | ELSEVIER SCIENCE INC |
| JCO Precision Oncology N/A |
5.600 | 5.400 | 1.090 | Q1 | LIPPINCOTT WILLIAMS & WILKINS |
| MOLECULAR CANCER THERAPEUTICS 1535-7163 |
5.500 | 5.700 | 1.210 | Q1 | AMER ASSOC CANCER RESEARCH |
| Cancer & Metabolism N/A |
5.300 | 5.800 | 1.080 | Q1 | BMC |
| Molecular Therapy Oncology N/A |
5.300 | 5.200 | 1.230 | Q1 | CELL PRESS |
| RADIOTHERAPY AND ONCOLOGY 0167-8140 |
5.300 | 5.600 | 1.370 | Q1 | ELSEVIER IRELAND LTD |
| Cancer Drug Resistance N/A |
5.200 | 5.300 | 0.760 | Q1 | OAE PUBLISHING INC |
| Oncology Reviews 1970-5565 |
5.200 | 3.900 | 0.440 | Q1 | FRONTIERS MEDIA SA |
| CANCER 0008-543X |
5.100 | 6.300 | 1.200 | Q1 | WILEY |
| CANCER IMMUNOLOGY IMMUNOTHERAPY 0340-7004 |
5.100 | 5.400 | 1.080 | Q1 | SPRINGER |
| Gastric Cancer 1436-3291 |
5.100 | 6.400 | 1.210 | Q1 | SPRINGER |
| CANCER GENE THERAPY 0929-1903 |
5.000 | 5.200 | 1.070 | Q1 | SPRINGERNATURE |
| Current Oncology Reports 1523-3790 |
5.000 | 5.400 | 0.710 | Q1 | SPRINGER |
| Blood and Lymphatic Cancer-Targets and Therapy 1179-9889 |
4.900 | 3.900 | 0.600 | Q1 | DOVE MEDICAL PRESS LTD |
| INTERNATIONAL JOURNAL OF ONCOLOGY 1019-6439 |
4.900 | 4.900 | 0.970 | Q1 | SPANDIDOS PUBL LTD |
| Cancer Nanotechnology 1868-6958 |
4.800 | 5.100 | 0.910 | Q1 | SPRINGER WIEN |
| CELLULAR ONCOLOGY 2211-3428 |
4.800 | 5.400 | 1.180 | Q1 | SPRINGER |
| CURRENT TREATMENT OPTIONS IN ONCOLOGY 1527-2729 |
4.700 | 4.700 | 0.620 | Q1 | SPRINGER |
| INTERNATIONAL JOURNAL OF CANCER 0020-7136 |
4.700 | 5.900 | 1.200 | Q1 | WILEY |
| INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 1048-891X |
4.700 | 4.600 | 1.330 | Q1 | BMJ PUBLISHING GROUP |
| MOLECULAR CANCER RESEARCH 1541-7786 |
4.700 | 4.900 | 0.840 | Q1 | AMER ASSOC CANCER RESEARCH |
| CANCER BIOLOGY & THERAPY 1538-4047 |
4.600 | 4.100 | 1.010 | Q1 | TAYLOR & FRANCIS INC |
| ENDOCRINE-RELATED CANCER 1351-0088 |
4.600 | 4.200 | 0.900 | Q1 | BIOSCIENTIFICA LTD |
| JCO Oncology Practice 2688-1527 |
4.600 | 4.300 | 0.870 | Q1 | LIPPINCOTT WILLIAMS & WILKINS |
| Molecular Oncology 1574-7891 |
4.500 | 5.700 | 1.040 | Q2 | WILEY |
| LUNG CANCER 0169-5002 |
4.400 | 4.500 | 1.100 | Q1 | ELSEVIER IRELAND LTD |
| CANCER SCIENCE 1347-9032 |
4.300 | 5.100 | 1.010 | Q2 | WILEY |
| ONCOLOGIST 1083-7159 |
4.200 | 5.000 | 0.970 | Q2 | OXFORD UNIV PRESS |
| Therapeutic Advances in Medical Oncology 1758-8340 |
4.200 | 4.200 | 0.800 | Q2 | SAGE PUBLICATIONS LTD |
| Gynecologic Oncology 0090-8258 |
4.100 | 4.400 | 1.330 | Q1 | ACADEMIC PRESS INC ELSEVIER SCIENCE |
| JNCI Cancer Spectrum N/A |
4.100 | 4.500 | 0.880 | Q2 | OXFORD UNIV PRESS |
| Journal of Cancer Science and Clinical Therapeutics 2637-5079 |
4.100 | 5.000 | 2.020 | Q1 | FORTUNE JOURNALS |
| Neuro-Oncology Advances N/A |
4.100 | 4.300 | 1.020 | Q1 | OXFORD UNIV PRESS |
| ONCOLOGY RESEARCH 0965-0407 |
4.100 | 3.500 | 0.850 | Q2 | TECH SCIENCE PRESS |
| Recent Patents on Anti-Cancer Drug Discovery 1574-8928 |
4.100 | 3.200 | 0.710 | Q1 | BENTHAM SCIENCE PUBL LTD |
| Translational Oncology 1936-5233 |
4.100 | 4.600 | 1.050 | Q2 | ELSEVIER SCIENCE INC |
| Targeted Oncology 1776-2596 |
4.000 | 4.400 | 0.920 | Q2 | SPRINGER |
| HEMATOLOGICAL ONCOLOGY 0278-0232 |
3.900 | 3.500 | 0.580 | Q1 | WILEY |
| ONCOLOGY REPORTS 1021-335X |
3.900 | 3.500 | 0.840 | Q2 | SPANDIDOS PUBL LTD |
| ORAL ONCOLOGY 1368-8375 |
3.900 | 4.600 | 1.090 | Q1 | ELSEVIER |
| Cancer Research and Treatment 1598-2998 |
3.800 | 3.800 | 1.030 | Q2 | KOREAN CANCER ASSOCIATION |
| Journal of Gastric Cancer 2093-582X |
3.800 | 2.900 | 0.850 | Q2 | KOREAN GASTRIC CANCER ASSOC |
| Journal of Gynecologic Oncology 2005-0380 |
3.700 | 3.500 | 1.120 | Q1 | KOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPY |
| ANNALS OF SURGICAL ONCOLOGY 1068-9265 |
3.500 | 3.600 | 1.220 | Q1 | SPRINGER |
| CANCER IMAGING 1740-5025 |
3.500 | 4.400 | 0.980 | Q1 | BMC |
| CURRENT CANCER DRUG TARGETS 1568-0096 |
3.500 | 2.900 | 0.540 | Q2 | BENTHAM SCIENCE PUBL LTD |
| Journal of Bone Oncology N/A |
3.500 | 3.600 | 0.700 | Q2 | ELSEVIER |
| MEDICAL ONCOLOGY 1357-0560 |
3.500 | 3.300 | 0.690 | Q2 | HUMANA PRESS INC |
| Practical Radiation Oncology 1879-8500 |
3.500 | 3.100 | 1.010 | Q1 | ELSEVIER SCIENCE INC |
| PSYCHO-ONCOLOGY 1057-9249 |
3.500 | 4.000 | 0.900 | Q1 | WILEY |
| Translational Lung Cancer Research 2218-6751 |
3.500 | 4.000 | 0.840 | Q1 | AME PUBLISHING COMPANY |
| BMC CANCER N/A |
3.400 | 3.700 | 0.800 | Q2 | BMC |
| Breast Cancer-Targets and Therapy 1179-1314 |
3.400 | 4.000 | 0.640 | Q2 | DOVE MEDICAL PRESS LTD |
Comparing oncology journals
Consider tumour type, clinical or translational focus, readership, indexing and article type together with journal-level metrics.